Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

28 janv. 2025 08h01 HE | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.
08 janv. 2025 08h02 HE | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
23 déc. 2024 08h57 HE | Source: Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.